Examples of CCL2/CCR2 axis antagonists undergoing early phase clinical trials include trabectedin, a CCL2 antagonist used to treat ovarian cancer [172], and cenicriviroc, a CCR2 (and CCR5) inhibitor currently progressing through clinical trials for MASH and fibrosis [173]. This evidence concerns the gene CCR2 and ovarian cancer.